Skip to main content

Table 3 Selected trials of alemtuzumab monotherapy and chemoimmunotherapy in CLL patients

From: Therapeutic advancement of chronic lymphocytic leukemia

Reference (year) Regimen Phase Number of patients Treatment status CR,% ORR,% Median PFS (months) Median OS (months)
Hillmen, 2007 [25] Alemtuzumab 3 149 Untreated 24 83 14.6 NR
  Chlorambucil   148 Untreated 2 55 11.7 NR
Gritti, 2012 [27] Alemtuzumab 2 18 F-ref 8 44 10.3 29.1
Stilgenbauer, 2011 [28] AD 2 30 Untreated, del(17p) 20 97 16.9 >24 , NR
   17 Relapse, del(17p) 0 76 10.4 15
   40 F-ref 5 70 8.4 12
Geisler, 2011 [29] AFC 3 129 Untreated, high-risk 57 88 37 NR
  FC   133 Untreated, high-risk 45 80 31 NR
Badoux, 2011 [30] CFAR 2 80 Refractory /relapse 29 65 10.6 N/A
Zent, 2011 [31] PAR 2 19 Refractory /relapse 32 74 7 23
  1. Abbreviations: A, alemtuzumab; AD, alemtuzumab and dexamethasone; AFC, alemtuzumab plus fludarabine and cyclophosphamide; CFAR, fludarabine, cyclophosphamide, alemtuzumab and rituximab; CR, complete response; FC, fludarabine and cyclophosphamide; F-ref, fludarabine-refractory; N/A, not applicable; NR, not researched; Not Rep, not reported; ORR, overall response rate; OS, overall survival; PAR, pentostatin, alemtuzumab, and rituximab.